Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. Aeglea's lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency. The PEACE study achieved the primary endpoint of plasma arginine reduction from baseline levels. Pronounced and sustained plasma arginine reduction was accompanied by a positive trend in the Gross Motor Function Measure Part E (GMFM-E), a key clinical assessment of a patient’s mobility. Aeglea and has received both Rare Pediatric Disease and Breakthrough Therapy Designations plans to submit a Biologics License Application to the U.S. Food and Drug Administration in the first half of 2022.